StageZero Life Sciences (TSX:SZLS) EV-to-EBIT : -0.40 (As of May. 01, 2024)

View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, StageZero Life Sciences's Enterprise Value is C$6.73 Mil. StageZero Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was C$-16.72 Mil. Therefore, StageZero Life Sciences's EV-to-EBIT for today is -0.40.

The historical rank and industry rank for StageZero Life Sciences's EV-to-EBIT or its related term are showing as below:

TSX:SZLS' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.1 Med: -2.98 Max: -0.22
Current: -0.4

During the past 13 years, the highest EV-to-EBIT of StageZero Life Sciences was -0.22. The lowest was -30.10. And the median was -2.98.

TSX:SZLS's EV-to-EBIT is ranked worse than
100% of 109 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.31 vs TSX:SZLS: -0.40

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. StageZero Life Sciences's Enterprise Value for the quarter that ended in Sep. 2023 was C$8.56 Mil. StageZero Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was C$-16.72 Mil. StageZero Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -195.36%.

StageZero Life Sciences EV-to-EBIT Historical Data

The historical data trend for StageZero Life Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences EV-to-EBIT Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

-2.54

-4.14

-4.97

-2.82

-0.58

StageZero Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															-2.03	-0.58	-0.73	-0.59	-0.51

Competitive Comparison of StageZero Life Sciences's EV-to-EBIT

For the Diagnostics & Research subindustry, StageZero Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StageZero Life Sciences's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's EV-to-EBIT falls into.

StageZero Life Sciences EV-to-EBIT Calculation

StageZero Life Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	6.733	/	-16.716
	=	-0.40

StageZero Life Sciences's current Enterprise Value is C$6.73 Mil.
StageZero Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-16.72 Mil.

StageZero Life Sciences (TSX:SZLS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

StageZero Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-16.716	/	8.556435
	=	-195.36 %

StageZero Life Sciences's Enterprise Value for the quarter that ended in Sep. 2023 was C$8.56 Mil.
StageZero Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-16.72 Mil.

StageZero Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences (TSX:SZLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

SZLSF:USA 61N1:Germany

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines